Diagnostic blood tests based on detection of carcinoembryonic antigen (CEA) are now widely used for CRC, but the sensitivity of this biomarker in early-stage cancer is only 5–10 % [1, 2]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.